Page last updated: 2024-11-04

hydroxymethylbilane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID788
CHEMBL ID273676
CHEBI ID16645
SCHEMBL ID18547975
MeSH IDM0082654

Synonyms (18)

Synonym
3,8,13,18-tetrakis(carboxymethyl)-19-(hydroxymethyl)bilane-2,7,12,17-tetrapropanoic acid
CHEBI:16645 ,
3,8,13,18-tetrakis(carboxymethyl)-5,10,15,22,23,24-hexahydro-19-(hydroxymethyl)-21h-biline-2,7,12,17-tetrapropanoic acid
71861-60-4
HYDROXYMETHYLBILANE ,
preuroporphyrinogen
C01024 ,
CHEMBL273676
3-[5-[[3-(2-carboxyethyl)-5-[[3-(2-carboxyethyl)-5-[[3-(2-carboxyethyl)-4-(carboxymethyl)-5-(hydroxymethyl)-1h-pyrrol-2-yl]methyl]-4-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-4-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-4-(carboxymethyl)-1h-pyrrol-3-yl]propanoic
3-(5-{[3-(2-carboxyethyl)-4-(carboxymethyl)-5-(hydroxymethyl)-1h-pyrrol-2-yl]methyl}-2-{[4-(2-carboxyethyl)-5-{[4-(2-carboxyethyl)-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl}-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl}-4-(carboxymethyl)-1h-pyrrol-3-yl)propanoic
SCHEMBL18547975
3-[2-[[4-(2-carboxyethyl)-5-[[4-(2-carboxyethyl)-5-[[4-(2-carboxyethyl)-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-4-(carboxymethyl)-5-(hydroxymethyl)-1h-pyrrol-3-yl]propanoic
3,8,13,18-tetrakis(carboxymethyl)-19-(hydroxymethyl)bilane-2,7,12,17-tetrapropanoate
3-[2-[[4-(2-carboxyethyl)-5-[[4-(2-carboxyethyl)-5-[[4-(2-carboxyethyl)-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-3-(carboxymethyl)-1h-pyrrol-2-yl]methyl]-4-(carboxymethyl)-5-(hydroxymethyl)-1h-pyrrol-3-yl]propanoat
3,8,13,18-tetrakis(carboxymethyl)-5,10,15,22,23,24-hexahydro-19-(hydroxymethyl)-21h-biline-2,7,12,17-tetrapropanoate
Q2639442
DTXSID001105025
hydroxymethylbilane(hmb)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bilanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
Porphyrin Metabolism1636
Acute Intermittent Porphyria1636
Porphyria Variegata (PV)1636
Congenital Erythropoietic Porphyria (CEP) or Gunther Disease1636
Hereditary Coproporphyria (HCP)1636
Porphyrin_metabolism ( Porphyrin metabolism )716
Biochemical pathways: part I0466
Heme biosynthesis012

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (18.18)18.7374
1990's9 (40.91)18.2507
2000's2 (9.09)29.6817
2010's6 (27.27)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.08 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index52.87 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]